CYP27A1 and familial hypercholesterolemia: We now demonstrate that the pharmacologic inhibition of cyp27a1 in the setting of hypercholesterolemia is antiatherogenic (Supplementary Fig. 10b), possibly revealing a means to intervene against hypercholesterolemia-related inflammation without disturbing innate or adaptive immune responses.